OBJECTIVE: To assess the effect of baseline variables, including treatment, on clinical cure and survival rates in patients with Gram-positive, ventilator-associated pneumonia (VAP). DESIGN: Retrospective analysis of two randomized, double-blind studies. SETTING:Multinational study with 134 sites. PATIENTS: 544 patients with suspected Gram-positive VAP, including 264 with documented Gram-positive VAP and 91 with methicillin-resistant S. aureus (MRSA) VAP. INTERVENTIONS:Linezolid 600 mg or vancomycin 1 g every 12 h for 7-21 days, each with aztreonam. MEASUREMENTS AND RESULTS:Clinical cure rates assessed 12-28 days after the end of therapy and excluding indeterminate or missing outcomes significantly favored linezolid in the Gram-positive and MRSA subsets. Logistic regression showed that linezolid was an independent predictor of clinical cure with odds ratios of 1.8 for all patients, 2.4 for Gram-positive VAP, and 20.0 for MRSA VAP. Kaplan-Meier survival rates favored linezolid in the MRSA subset. Logistic regression showed that linezolid was an independent predictor of survival with odds ratios of 1.6 for all patients, 2.6 for Gram-positive VAP, and 4.6 for MRSA VAP. CONCLUSIONS: Initial linezolid therapy was associated with significantly better clinical cure and survival rates than was initial vancomycin therapy in patients with MRSA VAP.
RCT Entities:
OBJECTIVE: To assess the effect of baseline variables, including treatment, on clinical cure and survival rates in patients with Gram-positive, ventilator-associated pneumonia (VAP). DESIGN: Retrospective analysis of two randomized, double-blind studies. SETTING: Multinational study with 134 sites. PATIENTS: 544 patients with suspected Gram-positive VAP, including 264 with documented Gram-positive VAP and 91 with methicillin-resistant S. aureus (MRSA) VAP. INTERVENTIONS:Linezolid 600 mg or vancomycin 1 g every 12 h for 7-21 days, each with aztreonam. MEASUREMENTS AND RESULTS: Clinical cure rates assessed 12-28 days after the end of therapy and excluding indeterminate or missing outcomes significantly favored linezolid in the Gram-positive and MRSA subsets. Logistic regression showed that linezolid was an independent predictor of clinical cure with odds ratios of 1.8 for all patients, 2.4 for Gram-positive VAP, and 20.0 for MRSA VAP. Kaplan-Meier survival rates favored linezolid in the MRSA subset. Logistic regression showed that linezolid was an independent predictor of survival with odds ratios of 1.6 for all patients, 2.6 for Gram-positive VAP, and 4.6 for MRSA VAP. CONCLUSIONS: Initial linezolid therapy was associated with significantly better clinical cure and survival rates than was initial vancomycin therapy in patients with MRSA VAP.
Authors: H Georges; O Leroy; S Alfandari; B Guery; M Roussel-Delvallez; C Dhennain; G Beaucaire Journal: Eur J Clin Microbiol Infect Dis Date: 1997-05 Impact factor: 3.267
Authors: M Cruciani; G Gatti; L Lazzarini; G Furlan; G Broccali; M Malena; C Franchini; E Concia Journal: J Antimicrob Chemother Date: 1996-11 Impact factor: 5.790
Authors: M Wysocki; F Delatour; F Faurisson; A Rauss; Y Pean; B Misset; F Thomas; J F Timsit; T Similowski; H Mentec; L Mier; D Dreyfuss Journal: Antimicrob Agents Chemother Date: 2001-09 Impact factor: 5.191
Authors: C Lamer; V de Beco; P Soler; S Calvat; J Y Fagon; M C Dombret; R Farinotti; J Chastre; C Gibert Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191
Authors: J Fagon; H Patrick; D W Haas; A Torres; C Gibert; W G Cheadle; R E Falcone; J D Anholm; F Paganin; T C Fabian; F Lilienthal Journal: Am J Respir Crit Care Med Date: 2000-03 Impact factor: 21.405
Authors: K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan Journal: Internist (Berl) Date: 2006-04 Impact factor: 0.743